Overall, molecular docking confirmed the strong binding abilities of VPA and ALA to the core targets, reinforcing the hypothesis that the synergistic effects of VPA and ALA in ALS treatment may be mediated through their interactions with TNF, EGFR, MAPK1, and MAPK8. The gene discussed is MAPK8; the disease is amyotrophic lateral sclerosis.